JOUNCE THERAPEUTICS INC (JNCE) 1.19 +0.06 (+5.31%)
1.19 +0.06 (+5.31%)
US4811161011 - Common Stock - After market: 1.2 +0.01 (+0.84%)
Fundamental Rating
Taking everything into account, JNCE scores 2 out of 10 in our fundamental rating. JNCE was compared to 639 industry peers in the Biotechnology industry. Both the profitability and financial health of JNCE have multiple concerns. While showing a medium growth rate, JNCE is valued expensive at the moment.
Note: JNCE has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
JNCE has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for JNCE.
VS Industry
Valuation
Valuation Rating
When comparing the current price to the book value of JNCE, it is valued rather cheaply. It is trading at 0.48 times its book value.
Compared to an average industry price book ratio of 1.87, JNCE is valued rather cheaply. On top of this, JNCE is cheaper than 86% of the companies listed in the same industry.
The Price/Earnings Ratio is negative for JNCE. In the last year negative earnings were reported.
Also next year JNCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Price/Book (0.48) VS Industry: 86% outperformed.
464.05
0.07
Growth
Growth Rating
JNCE is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 24.56% yearly.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
JNCE is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 6.51% yearly.
JNCE shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -6.27% yearly.
The earnings per share for JNCE have decreased strongly by -556.41% in the last year.
The Revenue for JNCE has decreased by -100.00% in the past year. This is quite bad
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -556.41% | -32.21% | -10.14% | -4.48% | 6.51% |
| Revenue | -6.27% | -25.55% | -100% | -80.88% | -51.66% | -68.3% | 24.56% |
Health
Health Rating
JNCE has a Current Ratio of 6.42. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
JNCE has a Quick Ratio of 6.42. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio is in line with the industry averages, which is at 6.21.
JNCE has a Quick Ratio comparable to the industry average, which is at 6.11.
The Debt to Equity ratio of JNCE is in line with the industry averages.
Based on the Altman-Z score of -3.64, we must say that JNCE is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of JNCE to the average industry Altman-Z score of -0.13, JNCE is less financially healthy than its industry peers.
JNCE has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for JNCE.
VS Industry
Debt/Equity (0) VS Industry: 42% outperformed.
15.37
0.00
Quick Ratio (6.42) VS Industry: 52% outperformed.
0.04
84.53
Current Ratio (6.42) VS Industry: 52% outperformed.
0.08
85.09
Altman-Z (-3.64) VS Industry: 31% outperformed.
-94.22
622.88
Dividend
Dividend Rating
JNCE does not give a dividend.
JOUNCE THERAPEUTICS INC1.19
NASDAQ:JNCE (1/27/2023, 7:17:20 PM)+0.06 (+5.31%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-10 2022-11-10/bmo | Earnings (Next) | 02-28 2023-02-28 |
| Inst Owners | 79.21% | Inst Owner Change | -0.67% |
| Ins Owners | 0.98% | Ins Owner Change | -12.82% |
| Market Cap | 61.52M | Analysts | 80 |
| Price Target | 6.12 (414.29%) | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS beat(2) | 2 | Avg EPS beat(2) | 6.81% |
| Min EPS beat(2) | 5.77% | Max EPS beat(2) | 7.85% |
| EPS beat(4) | 2 | Avg EPS beat(4) | -22.83% |
| Min EPS beat(4) | -82.18% | Max EPS beat(4) | 7.85% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | -100% |
| Min Revenue beat(2) | -100% | Max Revenue beat(2) | -100% |
| Revenue beat(4) | N/A | Avg Revenue beat(4) | -100% |
| Min Revenue beat(4) | -100% | Max Revenue beat(4) | -100% |
| PT rev (1m) | -3.23% | EPS NQ rev (1m) | 0% |
| EPS NY rev (1m) | 0% | Revenue NQ rev (1m) | 0% |
| Revenue NY rev (1m) | 0% | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.48 | ||
| P/tB | 0.48 | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -2.56 | EY | N/A |
| EPS(NY) | -2.23 | Fwd EY | N/A |
| FCF(TTM) | -2.27 | FCFY | N/A |
| OCF(TTM) | -2.25 | OCFY | N/A |
| SpS | N/A | BVpS | 2.5 |
| TBVpS | 2.5 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 2 | Asset Turnover | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 35.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.42 | ||
| Quick Ratio | 6.42 | ||
| Altman-Z | -3.64 |
| F-Score | 2 | WACC | 9.04% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 13.93% |
| Cap/Depr(5y) | 84.36% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | -556.41% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -1.69% |
| EPS Next Y | -32.21% | EPS Next 2Y | -10.14% |
| EPS Next 3Y | -4.48% | EPS Next 5Y | 6.51% |
| Revenue growth 1Y | -100% | Revenue growth 3Y | -25.55% |
| Revenue growth 5Y | -6.27% | Revenue growth Q2Q | N/A |
| Revenue Next Year | -80.88% | Revenue Next 2Y | -51.66% |
| Revenue Next 3Y | -68.3% | Revenue Next 5Y | 24.56% |
| EBIT growth 1Y | -423.27% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | N/A |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | -36.52% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | -35.72% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA